But there is also an IQVIA report that makes clear the cost of 340B to the average Joe
And why we should celebrate genericization
And I like BI's $35 inhaler pledge, even if I'm not tracking on the mechanics
And there is just an enormous pile of news to get through ...
And a must-read piece documenting the growth in access challenges in Part D
Plus a NYT guest essay that misses the point -- badly -- on where the obesity conversation needs to go
And some links from yesterday's Rare Disease Day hearing on the Hill
And Mr. Cuban goes to Washington
Plus some of the inside skinny on why Congress dropped PBM reform
Plus thoughts on an overly simplistic look at the cost-effectiveness of psoriasis drugs
And we're not having a constructive dialogue about gene therapy
And 2024's first drug-pricing announcement: Iovance's Amtagvi will run $515,000
